A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Kathleen N. Moore; Michael W. Sill; Meaghan E. Tenney; Christopher J. Darus; David Griffin; Theresa L. Werner; Peter G. Rose; Robert Behrens

doi:10.1016/j.ygyno.2015.07.006

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.07.006 ◽

2015 ◽

Vol 138 (3) ◽

pp. 513-518 ◽

Cited By ~ 24

Author(s):

Kathleen N. Moore ◽

Michael W. Sill ◽

Meaghan E. Tenney ◽

Christopher J. Darus ◽

David Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Group Trial ◽

Angiopoietin 1

Get full-text (via PubEx)

A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.055 ◽

2015 ◽

Vol 137 ◽

pp. 24 ◽

Cited By ~ 2

Author(s):

K.N. Moore ◽

M. Sill ◽

M.E. Tenney ◽

C.J. Darus ◽

D. Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Angiopoietin 1

Get full-text (via PubEx)

Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group study

American Journal of Clinical Oncology ◽

10.1097/00000421-198406000-00012 ◽

1984 ◽

Vol 7 (3) ◽

pp. 261-264 ◽

Cited By ~ 1

Author(s):

J. Tate Thigpen ◽

John A. Blessing ◽

James C. Arseneau ◽

Howard D. Homesley

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Carcinoma Of The Ovary

Get full-text (via PubEx)

Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group

Gynecologic Oncology ◽

10.1016/s0090-8258(88)80028-3 ◽

1988 ◽

Vol 31 (3) ◽

pp. 435-438 ◽

Cited By ~ 15

Author(s):

J. Tate Thigpen ◽

John A. Blessing ◽

Harrison Ball ◽

Parviz Hanjani ◽

Alberto Manetta ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

First Line ◽

Recurrent Carcinoma ◽

Line Chemotherapy

Get full-text (via PubEx)

Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group

International Journal of Gynecology & Obstetrics ◽

10.1016/0020-7292(89)90297-x ◽

1989 ◽

Vol 29 (3) ◽

pp. 282-282

Author(s):

JT Thigpen ◽

JA Blessing ◽

H Ball ◽

P Hanjani ◽

A Manetta ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

First Line ◽

Recurrent Carcinoma ◽

Line Chemotherapy

Get full-text (via PubEx)

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79492-6 ◽

2010 ◽

Vol 2010 ◽

pp. 69-70

Author(s):

J.T. Thigpen

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Line Treatment ◽

Second Line ◽

Oncology Group ◽

Group Trial

Get full-text (via PubEx)

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2003.12.021 ◽

2004 ◽

Vol 93 (1) ◽

pp. 144-148 ◽

Cited By ~ 23

Author(s):

Farr Nezhat ◽

Scott Wadler ◽

Franco Muggia ◽

John Mandeli ◽

Gary Goldberg ◽

...

Keyword(s):

New York ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Bryostatin 1 ◽

Oncology Group Study ◽

Recurrent Carcinoma

Get full-text (via PubEx)

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study)

American Journal of Obstetrics and Gynecology ◽

10.1016/0002-9378(89)90507-3 ◽

1989 ◽

Vol 161 (2) ◽

pp. 309-312 ◽

Cited By ~ 110

Author(s):

Gregory P. Sutton ◽

John A. Blessing ◽

Neil Rosenshein ◽

Guy Photopulos ◽

Philip J. DiSaia

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.02.013 ◽

2011 ◽

Vol 121 (3) ◽

pp. 455-461 ◽

Cited By ~ 33

Author(s):

Lydia Usha ◽

Michael W. Sill ◽

Kathleen M. Darcy ◽

Doris M. Benbrook ◽

Jean A. Hurteau ◽

...

Keyword(s):

Protein Kinase C ◽

Protein Kinase ◽

Phase Ii ◽

Prognostic Value ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Kinase C ◽

Predictive And Prognostic Value

Get full-text (via PubEx)